VeriMomtasmannia lanceolata leaf extract é seguro durante a gravidez?
No harmonised CLP reproductive classification (ECHA Annex VI) or SCCS/CIR safety assessment was identified for Tasmannia lanceolata leaf extract. A search of peer‑reviewed literature (PubMed) yields no controlled reproductive or developmental toxicity studies implicating this botanical; dominant constituents (e.g., polygodial) are described for irritancy/antimicrobial activity but not for teratogenicity. Therefore default hazard/mechanism scores are 0 and expected exposure from topical cosmetic use is low (e=0). Sources: ECHA Annex VI (no harmonised CLP entry), PubMed, CosIng, PubChem.
Pregnancy-safe products containing tasmannia lanceolata leaf extract
Related ingredients
Frequently asked questions
- tasmannia lanceolata leaf extract é seguro durante a gravidez?
- No harmonised CLP reproductive classification (ECHA Annex VI) or SCCS/CIR safety assessment was identified for Tasmannia lanceolata leaf extract. A search of peer‑reviewed literature (PubMed) yields no controlled reproductive or developmental toxicity studies implicating this botanical; dominant constituents (e.g., polygodial) are described for irritancy/antimicrobial activity but not for teratogenicity. Therefore default hazard/mechanism scores are 0 and expected exposure from topical cosmetic use is low (e=0). Sources: ECHA Annex VI (no harmonised CLP entry), PubMed, CosIng, PubChem.
- tasmannia lanceolata leaf extract é seguro durante a amamentação?
- No evidence in regulatory sources or peer‑reviewed literature of lactation-specific risks or transfer via breast milk for this ingredient. No harmonised classifications or CIR/SCCS opinions raising reproductive/lactational concerns. Topical cosmetic exposure is expected to be low for mother (e=0). Sources: PubMed, CosIng, ECHA Annex VI.
- tasmannia lanceolata leaf extract é seguro para a pele do bebê?
- No infant‑specific reproductive or developmental toxicity data found. Hazard and mechanism remain 0 due to absence of evidence of reproductive/ED effects. Exposure score increased by +1 (e=1) for 0–3‑year‑old skin because infant barrier immaturity increases potential percutaneous uptake relative to adults and because the ingredient is not an inherently non‑absorbable mineral; however, no data quantify neonatal absorption. Note: known concerns for this extract are primarily topical irritancy/allergenicity (from compositional constituents such as polygodial) rather than reproductive toxicity. Sources: PubMed, CosIng, EWG.
- Como o VeriMom pontua tasmannia lanceolata leaf extract?
- O VeriMom pontua tasmannia lanceolata leaf extract em 100/100 (sem riscos conhecidos) com base no status EU CosIng, classificações de perigo ECHA e estudos revisados por pares no PubMed. Nosso pipeline de pontuação é totalmente transparente.
- Quais são as alternativas seguras a tasmannia lanceolata leaf extract na gravidez?
- Veja nossa lista curada de alternativas seguras a tasmannia lanceolata leaf extract com base em função semelhante e classificação sem riscos conhecidos.
Verifique qualquer rótulo em 2 segundos
Baixe o VeriMom grátis — escaneie qualquer produto e veja a pontuação de segurança na gravidez instantaneamente.
Aviso Médico
Estas informações são apenas para fins educacionais e não constituem aconselhamento médico. As pontuações de segurança são baseadas em dados publicamente disponíveis e podem não refletir todos os riscos. Sempre consulte seu profissional de saúde antes de usar qualquer produto durante a gravidez ou amamentação.